July 21, 2015
Written by AIDSmeds
This post originally appeared on the AIDSmeds website.
Heterosexual participants in a study of Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis in Botswana apparently adhered to PrEP at very high rates, and there were no new HIV infections among them. The 229 participants in this open-label extension (OLE) phase of the TDF2 trial also reported taking fewer sexual risks during the year-long study. Results from the trial were presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, British Columbia.
There was no comparison, or control, group in this OLE trial, so the investigators will not publish an effectiveness rate estimating how well PrEP protected the participants against HIV. But when it comes to predicting how heterosexuals will likely adhere to PrEP outside of a study, the OLE phase may provide a more accurate projection than the randomized, double-blind, placebo-controlled phase of TDF2 that preceded it, and which was published in 2011. The OLE phase was set up to more closely resemble a real-world scenario, because, in contrast to the placebo-controlled trial, participants knew they were taking Truvada and were not paid to be in the study.